Journal of Patient-Centered
Research and Reviews
Volume 3

Issue 1

Article 1

1-25-2016

Asking Questions, Seeking Improvements
Dennis J. Baumgardner

Follow this and additional works at: https://aah.org/jpcrr
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Diseases
Commons, Medical Education Commons, and the Public Health Commons

Recommended Citation
Baumgardner DJ. Asking questions, seeking improvements. J Patient Cent Res Rev. 2016;3:6-8. doi:
10.17294/2330-0698.1253

Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the
Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal
focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes,
and the patient experience.

Asking Questions, Seeking Improvements
Dennis J. Baumgardner, MD │ Message from the Editor-in-Chief
Department of Family Medicine, Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI

As the Journal of Patient-Centered Research and
Reviews enters its third year, I’m proud to report our
product continues to improve with each issue. Since
its inaugural launch, JPCRR has expanded the scope
of its articles, delved deep into specific topics through
the use of theme issues and established an interactive
website with articles openly accessible by all visitors.
As a result of this steady and strategic growth, the
popularity of our humble journal has never been
stronger. What drives the demand for new journals and
the concomitant increase in article publishing capacity?
Fortunately, it is because interested professionals keep
asking questions and seeking improvements. It is this
quest for medical knowledge that ties together the
articles in this issue of JPCRR.
Just as the success of our journal has shown, clinical
breakthroughs don’t always have to be prohibitively
costly. To wit, Ortiz et al. describe on page 20 the
construction and validation of a scoring system
to help identify patients at high risk for access
site complications following peripheral vascular
intervention.1 This tool was relatively convenient to
develop using currently available clinical data, and
would be inexpensive to implement. By allowing
better case selection for the use of bleeding avoidance
strategies in patients believed to be at risk for
complications, outcomes of these interventions can be
improved. Simple improvements such as this scoring
system certainly address many of the core criteria
for health care (i.e. safe, effective, patient-centered,
timely, efficient, equitable) as outlined in the Institute
of Medicine’s report on quality health care for the 21st
century.2
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Also in this issue, Treiber and
Khandheria report a study
of patient echocardiograms
performed
with
and
without contrast.3 The use
of contrast significantly
improved the percentage of
endocardial walls visualized
and the percentage of
echocardiograms read with
high confidence by trained
cardiologists. This finding raises age-old questions.
Is new and improved always better? Is every new
technology cost-effective?
Historically, many new technologies (but certainly
not all) are ultimately found to be very cost-effective.4
Conversely, many new drugs have great success and
potential, but also stormy histories due to overuse,
misuse, overzealous marketing or inadequate control.
The history of antibiotics is an excellent example.5
In other cases, new drugs do not appear at first to be
an improvement over traditional ones;6 some perhaps
await dose optimization.7 Not uncommonly, drugs
used to treat one disease (e.g. cardiovascular disease)
may increase the risk of another disease (e.g. diabetes);
however, the overall benefit may still be positive.8
Similarly, new diagnostic tests may show considerable
promise, but ultimately do not meaningfully improve
disease detection or pose more harm than good.
Prostate-specific antigen testing is a case in point.9
Fictional biologist R. A. Janek from The Andromeda
Strain, a Michael Crichton novel on the outbreak of
a deadly extraterrestrial microorganism, is quoted as
saying “increasing vision is increasingly expensive.”10
Certainly, overuse of new technologies and resultant
poor clinical value for the dollar have been described in
cardiovascular medicine and many other disciplines.4,11,12
In the study by Treiber and Khandheria, the contrast
material used for the echocardiograms (perflutren lipid
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microsphere injectable suspension) is made of lipidcoated microspheres filled with octafluoropropane gas.
The cost of the material, however, is not excessive (a
few hundred dollars, depending on the institution), and
the addition of contrast appears to be cost-effective.
A 1998 study of a different proprietary contrast
agent resulted in a $269 per patient savings due to
reduced need for further testing.13 A 2002 study
examined contrast echocardiography in intensive
care unit patients. Compared to transesophageal
echocardiography, contrast echo resulted in cost
savings of 3% when evaluating regional ventricular
function and 17% when evaluating global ventricular
function.14 A more recent study of 632 consecutive
patients with technically difficult echocardiographic
examinations, which utilized the same contrast
agent as Treiber and Khandheria, documented a
$122 per patient savings with contrast.15 As with
any technological improvement, cost-effectiveness
analyses, proper case selection and use of intelligent
guidelines optimizes benefit.11
Inspired by a memorable patient encounter and the
integrative medicine theme of the preceding issue of
JPCRR, the review article on stinging nettle (p. 48)
illustrates a natural product that can cause both harm
and potential benefit.16 Botulinum toxin is another
obvious example of a naturally produced substance
with effects both bad and good.17 As with recent history
regarding botulinum toxin, well-designed translational
studies and clinical trials are needed to elucidate the
potential therapeutic uses of stinging nettle extracts.
Assuming that most future products derived from
stinging nettle are to be marketed as over-the-counter
supplements, rather than prescription drugs, the lack
of FDA requirement to prove effectiveness before
marketing may significantly limit the undertaking of
scientifically rigorous trials in this regard.18
Elsewhere in this issue, Nilakantan and colleagues
report that outcomes were worse among AfricanAmerican patients following renal transplantation
in a large hospital setting.19 While study sample size
may have limited some analyses, the etiologies of
this disparity appear to be multifactorial. Statistically
increased pretransplant time on dialysis was observed
for African-Americans compared to other racial
and ethnic groups. The authors suggest that this
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may have been the result of more limited access
to transplantation. Racial disparities have been
previously reported in renal transplant recipients (and,
of course, in many other chronic medical conditions).
While the etiologies of black/white disparities in
outcomes following medical interventions are poorly
understood and perhaps multifactorial, this issue is a
huge problem. Just for example, Ramamoorthy and
colleagues reported that approximately one-fifth of
new drugs approved by the FDA in the past 6 years
demonstrated differences in exposure and/or response
across racial and ethnic groups.20 Continued research,
specific drug labeling and clinician cognition of
racial differences in medical treatments are extremely
important in the care of our patients.
Proving that the best patient-centered research often
includes patients’ families, Winter et al. interviewed
83 patients with traumatic brain injury being cared for
at a Veterans Affairs medical rehabilitation service in
Philadelphia, along with their key family members.21
Family members identified nearly twice as many
problems as the veterans did themselves, and ranked
emotional and interpersonal problems the worst of
the various issues. The veterans, on the other hand,
listed cognitive and physical problems as their worst
issues. The authors conclude on page 37, “Veterans
may not recognize the concerns that are most upsetting
for family members, [and] family members may not
realize the problems most upsetting to veterans,” and
call for promoting dialogue around the target outcomes
for both parties. This paper is an excellent example of
patients and close family members “not being on the
same page” in the situation of chronic illness. Dietrich
von Engelhardt reminds us that “Disease is not just
a physical phenomenon, it is also a psychic, social,
and spiritual one.”22 As these components are deeply
personal,23 it makes sense that even very close family
members differ in their response and outlook regarding
a particular situation.
Similarly, desires of patients and their primary
clinicians also may vary, even when the relationship
is long-standing. Certainly, these differences may
become evident around issues of death and dying,24 but
also during more routine (but often critical) medical
decisions in which patient preferences conflict with
clinician judgment.25 Samuel Hellman urges us to
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continue to “learn while caring,” to see each “episode
of illness [as] the consequence of a unique interaction
of that individual with the disease,” and to “consider
the disease and its management in the context of each
patient’s values.23 Finally, von Engelhardt reminds us
that, “Medical science behaving as human medicine
should always and above all see the ill and suffering
person.”22
If this collection of original research and review
articles is any indication, the coming year is going
to be a fascinating and enlightening one at JPCRR.
There has been an explosion of new scientific journals
introduced in the past few years, but judging from
the strong contributions we have received and reader
response, the scientific community’s appetite for
knowledge justifies this evolution. While a number of
these newer publications are profit-minded and could
be deemed “predatory” journals,26 many others are
ethical publications dedicated to the spread of scientific
advancement.
JPCRR is pleased to be among the latter.
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